-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Luspatercept: A Treatment for Ineffective Erythropoiesis in Thalassemia

Program: Education Program
Session: Integrating New Therapies into the Management of Classical Heme Disorders
Saturday, December 7, 2024, 2:00 PM-3:15 PM

Ali T. Taher, MD, FRCP

Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Disclosures: Taher: Vifor: Consultancy, Research Funding; Pharmacosmos: Consultancy, Research Funding; Novo Nordisk: Consultancy; Bristol Myers Squibb (Celgene): Consultancy, Research Funding; Agios Pharmaceuticals, Inc.: Consultancy, Research Funding.

See more of: Integrating New Therapies into the Management of Classical Heme Disorders
See more of: Education Program
<< Previous Presentation | Next Presentation >>